A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Completed · Phase 2 · Has a placebo group

Conditions studied: Non-obstructive Hypertrophic Cardiomyopathy

In brief

This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2 target drug concentrations.

Key facts

Study ID
NCT03442764
Run by
MyoKardia, Inc.
People needed
59
Starts
2018-03-30
Expected to finish
2020-01-07
Last updated by the study team
2022-08-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.